CAPLIN POINT LABORATORIES LTD. - 524742 - Compliance Certificate In Terms Of Regulation 40 (10) Of The SEBI (LODR) Regulations, 2015 (Listing Regulations) For The Year Ended 31St March 2023.
Please find enclosed the Compliance Certificate, issued by M. Alagar and Associates, Chennai, Practicing Company Secretaries, in terms of Regulation 40 (9) of the Listing Regulations, for the year ended 31st March 2023. CAPLIN POINT LABORATORIES LTD. - 524742 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
This is to inform that mentioned share certificate has been reported as lost by the shareholder of the Company. CAPLIN POINT LABORATORIES LTD. - 524742 - Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A
Format of Initial Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1Name of CompanyCAPLIN POINT LABORATORIES LTD. 2CIN NO.L24231TN1990PLC019053 3 Outstanding borrowing of company as on 31st March / 31st December, as applicable (in Rs cr) 0.00 4Highest Credit Rating during the previous FY NA 4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)Not Applicable 5Name of Stock Exchange# in which the fine shall be paid, in case of shortfall in the required borrowing under the frameworkBSE We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018. No Name of the Company Secretary: Venkatram G Designation: Company Secretary and Compliance Officer EmailId: [email protected] Name of the Chief Financial Officer: D Muralidharan Designation: Chief Financial Officer EmailId: [email protected] Date: 21/04/2023 Note: In terms para of 3.2(ii) of the circular, beginning F.Y 2022, in the event of shortfall in the mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore, an entity identified as LC shall provide, in its initial disclosure for a financial year, the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets. CAPLIN POINT LABORATORIES LTD. - 524742 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
This is to inform that mentioned share certificates has been reported as lost by the shareholder of the Company. CAPLIN POINT LABORATORIES LTD. - 524742 - Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS
Allotment of Equity Shares on Exercise of ESOPs CAPLIN POINT LABORATORIES LTD. - 524742 - Closure of Trading Window
Pursuant to the provisions of SEBI (Prohibition of Insider Trading) Regulations, 2015 and in terms of the Company''s Code of Fair Disclosure and Code of Conduct to regulate, monitor and report trading by Insiders (''the Code''), the Trading Window for dealing in the shares of the Company will remain closed from April 01, 2023. CAPLIN POINT LABORATORIES LTD. - 524742 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
We submit herewith a Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, received from Integrated Registry Management Services Private Limited, the Registrar and Transfer Agent of the Company, for the quarter ended March 31, 2023 CAPLIN POINT LABORATORIES LTD. - 524742 - Compliance Certificate For The Year Ended March 31, 2023
We attach herewith Compliance Certificate in terms of Regulation 7(3) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, for the year ended March 31, 2023. CAPLIN POINT LABORATORIES LTD. - 524742 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
This is to inform that mentioned share certificates has been reported as lost by the shareholders of the Company CAPLIN POINT LABORATORIES LTD. - 524742 - Announcement under Regulation 30 (LODR)-Diversification / Disinvestment
Proposed Sale of Subsidiary Company